Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
900.16
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
Next >
Regeneron Announces Investor Conference Presentations
January 31, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
January 30, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis
January 27, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation’s Oldest and Most Prestigious Science and Math Competition
January 24, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Four Undervalued Healthcare Stocks for 2023
January 06, 2023
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.
Via
MarketBeat
Exposures
COVID-19
Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast on February 3, 2023
January 03, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
3 Mid-Caps That Could Double in 2023
December 15, 2022
Mid-cap land has long been regarded as the ‘sweet spot’ for equity investors. Here are three mid-caps Wall Street sees as two-baggers over the next 12 months.
Via
MarketBeat
Harpoon Therapeutics Remains Volatile After Promising News
December 14, 2022
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%.
Via
MarketBeat
CytomX Therapeutics (NASDAQ: CTMX) and Regeneron (NASDAQ: REGN) Enter into Strategic Collaboration to Develop Bispecific Therapies to Treat Cancer
November 17, 2022
CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a clinical-stage biopharmaceutical company, which is focused on developing innovative treatments for a wide-range
Via
Spotlight Growth
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
November 11, 2022
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
Via
MarketBeat
Why These 3 Stocks Are Off to Hot September Starts
September 13, 2022
Let’s look at what is behind the surprise rise in these three names—and whether they can continue to pace this month’s market rally.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Air Pollution is a Global Heart and Lung Health Concern
July 18, 2022
Palm Beach, FL – July 18, 2022 – FinancialNewsMedia.com News Commentary – Particulate matter or particle pollution is a significant contributor to heart and lung disease. Individuals most affected by...
Via
FinancialNewsMedia
Topics
Climate Change
Emissions
Energy
Exposures
Climate
Fossil Fuels
NASDAQ:REGN Investor Notice: Investigation over Potential Wrongdoing at Regeneron Pharmaceuticals, Inc.
May 31, 2022
San Diego, CA -- (SBWIRE) -- 05/31/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Regeneron Pharmaceuticals, Inc.
Via
SBWire
NASDAQ: REGN Shareholder Notice: Investigation over Possible Securities Laws Violations by Regeneron Pharmaceuticals, Inc.
April 15, 2022
San Diego, CA -- (SBWIRE) -- 04/15/2022 -- Regeneron Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Regeneron Pharmaceuticals Inc. (REGN) Climbs to Annual-High Share Price
March 21, 2022
Via
Investor Brand Network
Regeneron Pharmaceuticals Inc. (REGN) Climbs to Annual-High Share Price
March 21, 2022
Via
Investor Brand Network
Promising Results Continue to Develop Optimism in Fight Against Cancers
January 27, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 27, 2021 – USA News Group – There’s plenty of optimism surrounding the major medical breakthroughs targeting multiple types...
Via
FinancialNewsMedia
Global Alzheimer’s Disease Therapeutics Market Projected To Generate Revenue Of $9.97 Billion By 2028
January 04, 2022
Palm Beach, FL –January 4, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease is a degenerative, progressive ailment that attacks the brain’s nerve cells, resulting in memory loss,...
Via
FinancialNewsMedia
Exposures
COVID-19
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
October 11, 2021
Palm Beach, FL –October 11, 2021 – FinancialNewsMedia.com News Commentary – With the arrival of the COVID-19 virus, the antivirals market had all eyes watching the ongoing frenetic rush to find a cure...
Via
FinancialNewsMedia
Exposures
COVID-19
Increased Prevalence of Atopic Dermatitis Fueling Impressive Growth for Atopic Dermatitis Drugs
November 30, 2021
Palm Beach, FL –November 30, 2021 – FinancialNewsMedia.com News Commentary – Atopic dermatitis is a chronic inflammatory skin condition characterized by red, itchy, swollen, and broken skin. White...
Via
FinancialNewsMedia
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.